Stockscreener 앱 받기
577.63
1.03%
5.90
시장 영업 전:
577.63
전일 마감가:
$571.73
열려 있는:
$571.33
하루 거래량:
452.53K
Relative Volume:
0.94
시가총액:
$25.32B
수익:
$3.18B
순이익/손실:
$1.33B
주가수익비율:
20.70
EPS:
27.9001
순현금흐름:
$1.04B
1주 성능:
+3.21%
1개월 성능:
+7.74%
6개월 성능:
+31.26%
1년 성능:
+105.45%
1일 변동 폭
$569.70
$580.07
1주일 범위
$557.25
$586.01
52주 변동 폭
$272.12
$607.89
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
577.63 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.08 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.83 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.15 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock By Investing.com - Investing.com India
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock - Investing.com
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
UTHR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus
Raymond James initiates United Therapeutics stock coverage with outperform rating - Investing.com Australia
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock - Investing.com Australia
Raymond James initiates United Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
United Therapeutics’ liver device gets FDA regenerative therapy status - Investing.com
Bioengineered liver for acute liver failure gets key FDA designation - Stock Titan
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock - MarketBeat
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock By Investing.com - Investing.com Australia
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock - Investing.com
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher - MSN
Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Element Squared LLC Acquires New Position in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will United Therapeutics (UTHR) Surpass Expectations in Its Upcoming Earnings Announcement? - Bitget
United Therapeutics' Strong Competitive Edge and Robust Cash Flow Indicate a Sustainable Value Opportunity - Bitget
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,610,605.00 in Stock - MarketBeat
UNITED THERAPEUTICS CORP (UTHR.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
Allspring Global Investments Holdings LLC Has $52.05 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win (UTHR) - Seeking Alpha
United Therapeutics Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
BKMC Volume Surges 38-Fold as United Therapeutics Jumps - TipRanks
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CFO exercises options and sells 10k shares - Stock Titan
UNITED THERAPEUTICS (UTHR) director exercises options and sells 1,300 shares under 10b5-1 plan - Stock Titan
UNITED THERAPEUTICS (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo Finance UK
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $660.00 at HC Wainwright - MarketBeat
United Therapeutics (UTHR): Analyst Greg Harrison Raises Price T - GuruFocus
United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo - 247wallst.com
Retirement Systems of Alabama Has $47.39 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last? - Yahoo Finance
United Therapeutics Corp (UTHR) Stock Price Up 13.08% on Mar 30 - GuruFocus
United Therapeutics (UTHR) Achieves Key Milestone in IPF Treatme - GuruFocus
United Therapeutics (UTHR) Sees Positive Results in TETON-1 Stud - GuruFocus
United Therapeutics (UTHR) Tyvaso Shows Promising Results in TET - GuruFocus
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.67%
1.99%
자본화:
|
볼륨(24시간):